isoniazid has been researched along with Adverse Drug Event in 121 studies
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.
hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Weekly rifapentine plus isoniazid for 3 months (3HP) is as effective as daily isoniazid for 9 months (9H) for latent tuberculosis infection in high-risk persons, but there have been reports of possible flu-like syndrome." | 9.20 | Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study. ( Adkinson, NF; Borisov, AS; Ho, C; Moro, RN; Phillips, E; Shepherd, G; Sterling, TR; Villarino, ME; Weis, S, 2015) |
| "Three months of weekly rifapentine plus isoniazid (3HP) therapy for latent tuberculosis infection (LTBI) is recommended worldwide." | 8.31 | Symptoms and Systemic Drug Reactions in Persons Receiving Weekly Rifapentine Plus Isoniazid (3HP) Treatment for Latent Tuberculosis Infection. ( Belknap, R; Borisov, A; Caylà, JA; Chen, MP; Gandhi, NR; Holland, DP; Millet, JP; Moro, RN; Sadowski, C; Scott, NA; Wright, A, 2023) |
| "An important problem limiting treatment of latent tuberculosis infection is the occurrence of adverse events with isoniazid." | 7.96 | Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials. ( Adjobimey, M; Benedetti, A; Campbell, JR; Cook, VJ; Eisenbeis, L; Fregonese, F; Johnston, JC; Menzies, D; Ruslami, R; Trajman, A; Valiquette, C, 2020) |
| "Weekly rifapentine and isoniazid therapy (3HP) is the most frequent treatment for latent tuberculosis infection (LTBI)." | 7.91 | Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis. ( Chen, WW; Chiou, HL; Huang, WC; Huang, YW; Lin, CH; Tsao, SM; Yang, SF; Yang, WT; Yu, YY, 2019) |
| "The consequences of once-weekly rifapentine plus isoniazid for 3 months (3HP) against latent tuberculosis infections in hemodialysis patients have not been studied before." | 7.91 | Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: High rates of adverse events. ( Chen, TC; Chen, YH; Chiu, YW; Hsieh, MH; Hwang, SJ; Lin, SY; Lu, PL, 2019) |
| "Simultaneous administration of phenytoin and isoniazid (INH) in tuberculous meningitis (TBM) or tuberculoma patients with seizures results in higher plasma phenytoin level and thus phenytoin intoxication." | 7.83 | N-acetyltransferase 2 (NAT2) gene polymorphism as a predisposing factor for phenytoin intoxication in tuberculous meningitis or tuberculoma patients having seizures - A pilot study. ( Adole, PS; Kharbanda, PS; Sharma, S, 2016) |
| "Objective Treating latent tuberculosis infection (LTBI) is essential for eliminating the serious endemicity of tuberculosis." | 5.56 | Use of Rifampin Compared with Isoniazid for the Treatment of Latent Tuberculosis Infection in Japan: A Bayesian Inference with Markov Chain Monte Carlo Method. ( Iwata, K; Miyakoshi, C; Morishita, N; Nishiwaki, M, 2020) |
| "Weekly rifapentine plus isoniazid for 3 months (3HP) is as effective as daily isoniazid for 9 months (9H) for latent tuberculosis infection in high-risk persons, but there have been reports of possible flu-like syndrome." | 5.20 | Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study. ( Adkinson, NF; Borisov, AS; Ho, C; Moro, RN; Phillips, E; Shepherd, G; Sterling, TR; Villarino, ME; Weis, S, 2015) |
| "A population pharmacokinetic (PPK) study of the correlation of adverse drug reactions (ADRs) with the 3HP regimen (weekly high-dose rifapentine plus isoniazid for 12 doses) for latent tuberculosis infection (LTBI) remains lacking." | 4.31 | Isoniazid level and flu-like symptoms during rifapentine-based tuberculosis preventive therapy: A population pharmacokinetic analysis. ( Fujita, Y; Huang, HL; Ieiri, I; Lee, CH; Lee, MC; Muraki, S; Wang, JY, 2023) |
| "Three months of weekly rifapentine plus isoniazid (3HP) therapy for latent tuberculosis infection (LTBI) is recommended worldwide." | 4.31 | Symptoms and Systemic Drug Reactions in Persons Receiving Weekly Rifapentine Plus Isoniazid (3HP) Treatment for Latent Tuberculosis Infection. ( Belknap, R; Borisov, A; Caylà, JA; Chen, MP; Gandhi, NR; Holland, DP; Millet, JP; Moro, RN; Sadowski, C; Scott, NA; Wright, A, 2023) |
| "Systemic drug reaction (SDR) is a major safety concern with weekly rifapentine plus isoniazid for 12 doses (3HP) for latent tuberculosis infection (LTBI)." | 4.12 | Whole-Blood 3-Gene Signature as a Decision Aid for Rifapentine-based Tuberculosis Preventive Therapy. ( Cheng, MH; Chong, IW; Huang, HL; Huang, SH; Huang, YW; Lee, CH; Lee, JY; Lee, MR; Liu, IH; Lo, YS; Lu, PL; Wang, JY; Yang, JM, 2022) |
| "An important problem limiting treatment of latent tuberculosis infection is the occurrence of adverse events with isoniazid." | 3.96 | Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials. ( Adjobimey, M; Benedetti, A; Campbell, JR; Cook, VJ; Eisenbeis, L; Fregonese, F; Johnston, JC; Menzies, D; Ruslami, R; Trajman, A; Valiquette, C, 2020) |
| "Weekly rifapentine and isoniazid therapy (3HP) is the most frequent treatment for latent tuberculosis infection (LTBI)." | 3.91 | Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis. ( Chen, WW; Chiou, HL; Huang, WC; Huang, YW; Lin, CH; Tsao, SM; Yang, SF; Yang, WT; Yu, YY, 2019) |
| "The consequences of once-weekly rifapentine plus isoniazid for 3 months (3HP) against latent tuberculosis infections in hemodialysis patients have not been studied before." | 3.91 | Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: High rates of adverse events. ( Chen, TC; Chen, YH; Chiu, YW; Hsieh, MH; Hwang, SJ; Lin, SY; Lu, PL, 2019) |
| " The secondary objective was to determine the overall incidence of hepatitis in children on Anti tubercular treatment (ATT) and isoniazid prophylactic therapy (IPT)." | 3.91 | Revised Antituberculosis Drug Doses and Hepatotoxicity in HIV Negative Children. ( Indumathi, CK; Jain, S; Krishnamurthy, S; Sethuraman, A, 2019) |
| "Randomized controlled trials have demonstrated that the newest latent tuberculosis (LTBI) regimen, 12 weekly doses of directly observed isoniazid and rifapentine (3HP), is as efficacious as 9 months of isoniazid, with a greater completion rate (82% vs 69%); however, 3HP has not been assessed in routine healthcare settings." | 3.85 | High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection. ( Bamrah-Morris, S; Chorba, T; Griffin, P; Ho, CS; Holcombe, JM; Hunt, G; Jereb, J; Lobato, MN; Marco, A; Marks, S; Mase, S; Moro, RN; Mukasa, L; Nwana, N; Patil, N; Sandul, AL; Shah, N; Stewart, B; Wang, SH; Webb, R, 2017) |
| "Simultaneous administration of phenytoin and isoniazid (INH) in tuberculous meningitis (TBM) or tuberculoma patients with seizures results in higher plasma phenytoin level and thus phenytoin intoxication." | 3.83 | N-acetyltransferase 2 (NAT2) gene polymorphism as a predisposing factor for phenytoin intoxication in tuberculous meningitis or tuberculoma patients having seizures - A pilot study. ( Adole, PS; Kharbanda, PS; Sharma, S, 2016) |
| "Standard treatment of active tuberculosis (TB) consists of isoniazid (INH), rifampin (RMP), pyrazinamide (PZA) and ethambutol (EMB)." | 3.74 | Adverse drug reactions associated with first-line anti-tuberculosis drug regimens. ( Bruchet, N; Elwood, RK; Fitzgerald, JM; Marra, CA; Marra, F; Moadebi, S; Richardson, K, 2007) |
| "Among 69 patients with drug rash with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) to FLDs, FLDs were stopped and SLDs added when the skin and laboratory parameters had settled." | 2.80 | Lack of cross-toxicity between isoniazid and ethionamide in severe cutaneous adverse drug reactions: a series of 25 consecutive confirmed cases. ( Dheda, K; Dlamini, S; Gantsho, N; Lehloenya, RJ; Muloiwa, R; Todd, G, 2015) |
| " The ingestion of these first-line TB drugs are, however, not free of side effects, and are toxic to the liver, kidney, and central nervous system." | 2.66 | Metabolomics describes previously unknown toxicity mechanisms of isoniazid and rifampicin. ( Combrink, M; du Preez, I; Loots, DT, 2020) |
| "Seizures are commonly encountered in patients who do not have epilepsy." | 2.40 | Medical causes of seizures. ( Delanty, N; French, JA; Vaughan, CJ, 1998) |
| "We used the Korea Adverse Event Reporting System (KAERS) database (2009-2018)." | 1.72 | Analysis of Adverse Drug Reactions to First-Line Anti-Tuberculosis Drugs Using the Korea Adverse Event Reporting System. ( Byeon, SJ; Choi, JH; Chung, SJ, 2022) |
| "Objective Treating latent tuberculosis infection (LTBI) is essential for eliminating the serious endemicity of tuberculosis." | 1.56 | Use of Rifampin Compared with Isoniazid for the Treatment of Latent Tuberculosis Infection in Japan: A Bayesian Inference with Markov Chain Monte Carlo Method. ( Iwata, K; Miyakoshi, C; Morishita, N; Nishiwaki, M, 2020) |
| "The currently preferred regimen for treatment of pulmonary tuberculosis (PTB) is isoniazid, rifampin, pyrazinamide, and ethambutol, which has been used either as separate tablets (ST) or as fixed-dose combination (FDC)." | 1.46 | Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar. ( Al-Shaer, MH; Elewa, H; Iqbal, F; Mansour, H; Salameh, P, 2017) |
| "Isoniazid continues to be a leading cause of DILI in the United States, and its hepatotoxicity is under-reported significantly." | 1.42 | Under-reporting and Poor Adherence to Monitoring Guidelines for Severe Cases of Isoniazid Hepatotoxicity. ( Chalasani, NP; Davern, TJ; Fontana, RJ; Gu, J; Hayashi, PH; Hoofnagle, JH; Kleiner, DE; Lee, WM; Navarro, VJ; Stolz, AA; Talwalkar, JA, 2015) |
| "Isoniazid is a rare overdose that causes seizures and there is limited evidence to guide treatment." | 1.42 | Isoniazid poisoning: Pharmacokinetics and effect of hemodialysis in a massive ingestion. ( Isbister, GK; Medley, G; Mostafa, A; Roberts, MS; Saiao, A; Skinner, K; Soderstrom, J, 2015) |
| "To assess outcome and adverse drug events with a standardised 12-month regimen for MDR-TB among second-line drug naïve patients." | 1.42 | High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. ( Abena Foe, JL; Aït-Khaled, N; Kuaban, C; Noeske, J; Rieder, HL; Trébucq, A, 2015) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| "5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects." | 1.32 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. ( Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004) |
| " Although risk-assessment procedures that attempt to utilize the quantitative information in such data have been proposed, there is no general agreement that these procedures are appreciably more efficient than common quantal dose-response procedures that operate on dichotomized continuous data." | 1.30 | A comparison of methods of benchmark-dose estimation for continuous response data. ( Kodell, RL; West, RW, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 68 (56.20) | 18.7374 |
| 1990's | 3 (2.48) | 18.2507 |
| 2000's | 10 (8.26) | 29.6817 |
| 2010's | 27 (22.31) | 24.3611 |
| 2020's | 13 (10.74) | 2.80 |
| Authors | Studies |
|---|---|
| Matthews, EJ | 1 |
| Kruhlak, NL | 1 |
| Weaver, JL | 1 |
| Benz, RD | 1 |
| Contrera, JF | 1 |
| Pedersen, JM | 1 |
| Matsson, P | 1 |
| Bergström, CA | 1 |
| Norinder, U | 1 |
| Hoogstraate, J | 1 |
| Artursson, P | 1 |
| Chen, M | 1 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 2 |
| Fang, H | 2 |
| Tong, W | 2 |
| Dawson, S | 1 |
| Stahl, S | 1 |
| Paul, N | 1 |
| Barber, J | 1 |
| Kenna, JG | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Sakatis, MZ | 1 |
| Reese, MJ | 1 |
| Harrell, AW | 1 |
| Taylor, MA | 1 |
| Baines, IA | 1 |
| Chen, L | 1 |
| Bloomer, JC | 1 |
| Yang, EY | 1 |
| Ellens, HM | 1 |
| Ambroso, JL | 1 |
| Lovatt, CA | 1 |
| Ayrton, AD | 1 |
| Clarke, SE | 1 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Nanyonga, SM | 1 |
| Kitutu, FE | 1 |
| Kalyango, J | 1 |
| Frank, M | 1 |
| Kiguba, R | 1 |
| Huang, HL | 2 |
| Lee, JY | 1 |
| Lo, YS | 1 |
| Liu, IH | 1 |
| Huang, SH | 1 |
| Huang, YW | 2 |
| Lee, MR | 1 |
| Lee, CH | 3 |
| Cheng, MH | 1 |
| Lu, PL | 2 |
| Wang, JY | 2 |
| Yang, JM | 1 |
| Chong, IW | 1 |
| Chung, SJ | 1 |
| Byeon, SJ | 1 |
| Choi, JH | 1 |
| Lee, MC | 1 |
| Fujita, Y | 1 |
| Muraki, S | 1 |
| Ieiri, I | 1 |
| Daly, AK | 3 |
| Holmes, RH | 1 |
| Sun, S | 1 |
| Kazi, S | 1 |
| Ranganathan, S | 1 |
| Tosif, S | 1 |
| Graham, SM | 1 |
| Graham, HR | 1 |
| Sadowski, C | 1 |
| Belknap, R | 1 |
| Holland, DP | 1 |
| Moro, RN | 3 |
| Chen, MP | 2 |
| Wright, A | 1 |
| Millet, JP | 1 |
| Caylà, JA | 1 |
| Scott, NA | 2 |
| Borisov, A | 1 |
| Gandhi, NR | 1 |
| Campbell, JR | 1 |
| Trajman, A | 1 |
| Cook, VJ | 1 |
| Johnston, JC | 1 |
| Adjobimey, M | 1 |
| Ruslami, R | 1 |
| Eisenbeis, L | 1 |
| Fregonese, F | 1 |
| Valiquette, C | 1 |
| Benedetti, A | 1 |
| Menzies, D | 2 |
| Yu, YY | 1 |
| Tsao, SM | 1 |
| Yang, WT | 1 |
| Huang, WC | 1 |
| Lin, CH | 1 |
| Chen, WW | 1 |
| Yang, SF | 1 |
| Chiou, HL | 1 |
| Combrink, M | 1 |
| Loots, DT | 1 |
| du Preez, I | 1 |
| Liu, F | 1 |
| Jiang, FB | 1 |
| Li, YT | 1 |
| Liu, RM | 1 |
| Wu, ZY | 1 |
| Yan, CW | 1 |
| Iwata, K | 1 |
| Morishita, N | 1 |
| Nishiwaki, M | 1 |
| Miyakoshi, C | 1 |
| Bourhia, M | 1 |
| Ullah, R | 1 |
| S Alqahtani, A | 1 |
| Ibenmoussa, S | 1 |
| Greybe, L | 1 |
| Morrison, JL | 1 |
| Schaaf, HS | 1 |
| Rabie, H | 1 |
| Cotton, MF | 1 |
| Sandul, AL | 1 |
| Nwana, N | 1 |
| Holcombe, JM | 1 |
| Lobato, MN | 1 |
| Marks, S | 1 |
| Webb, R | 1 |
| Wang, SH | 1 |
| Stewart, B | 1 |
| Griffin, P | 1 |
| Hunt, G | 1 |
| Shah, N | 1 |
| Marco, A | 1 |
| Patil, N | 1 |
| Mukasa, L | 1 |
| Jereb, J | 1 |
| Mase, S | 1 |
| Chorba, T | 1 |
| Bamrah-Morris, S | 1 |
| Ho, CS | 1 |
| Lin, SY | 1 |
| Chiu, YW | 1 |
| Hwang, SJ | 1 |
| Chen, TC | 1 |
| Hsieh, MH | 1 |
| Chen, YH | 1 |
| Indumathi, CK | 1 |
| Sethuraman, A | 1 |
| Jain, S | 1 |
| Krishnamurthy, S | 1 |
| Khan, N | 1 |
| Mendonca, L | 1 |
| Dhariwal, A | 1 |
| Fontes, G | 1 |
| Xia, J | 1 |
| Divangahi, M | 1 |
| King, IL | 1 |
| Kurt, OK | 1 |
| Kurt, B | 1 |
| Talay, F | 1 |
| Tug, T | 1 |
| Soy, M | 1 |
| Bes, C | 1 |
| Hayran, M | 1 |
| Ahui, BJ | 1 |
| Horo, K | 1 |
| Bakayoko, AS | 1 |
| Kouassi, AB | 1 |
| Anon, JC | 1 |
| Brou-Gode, VC | 1 |
| Koffi, MO | 1 |
| Itchy, MV | 1 |
| N'Gom, AS | 1 |
| N'Goran, NB | 1 |
| Aka-Danguy, E | 1 |
| Hayashi, PH | 1 |
| Fontana, RJ | 2 |
| Chalasani, NP | 1 |
| Stolz, AA | 1 |
| Talwalkar, JA | 1 |
| Navarro, VJ | 1 |
| Lee, WM | 1 |
| Davern, TJ | 1 |
| Kleiner, DE | 1 |
| Gu, J | 1 |
| Hoofnagle, JH | 1 |
| Skinner, K | 1 |
| Saiao, A | 1 |
| Mostafa, A | 1 |
| Soderstrom, J | 1 |
| Medley, G | 1 |
| Roberts, MS | 1 |
| Isbister, GK | 1 |
| Kuaban, C | 1 |
| Noeske, J | 1 |
| Rieder, HL | 1 |
| Aït-Khaled, N | 1 |
| Abena Foe, JL | 1 |
| Trébucq, A | 1 |
| Sterling, TR | 2 |
| Borisov, AS | 1 |
| Phillips, E | 1 |
| Shepherd, G | 1 |
| Adkinson, NF | 1 |
| Weis, S | 1 |
| Ho, C | 1 |
| Villarino, ME | 2 |
| Andrade, RJ | 1 |
| Lehloenya, RJ | 1 |
| Muloiwa, R | 1 |
| Dlamini, S | 1 |
| Gantsho, N | 1 |
| Todd, G | 1 |
| Dheda, K | 1 |
| Miro, JM | 1 |
| Calvet, G | 1 |
| La Rosa, A | 1 |
| Infante, R | 1 |
| Benator, DA | 1 |
| Gordin, F | 1 |
| Benson, CA | 1 |
| Chaisson, RE | 1 |
| Adole, PS | 1 |
| Kharbanda, PS | 1 |
| Sharma, S | 1 |
| Al-Shaer, MH | 1 |
| Mansour, H | 1 |
| Elewa, H | 1 |
| Salameh, P | 1 |
| Iqbal, F | 1 |
| Marzano, AV | 1 |
| Vezzoli, P | 1 |
| Crosti, C | 1 |
| Liss, G | 1 |
| Rattan, S | 1 |
| Lewis, JH | 1 |
| Stirnimann, G | 1 |
| Kessebohm, K | 1 |
| Lauterburg, B | 1 |
| Villar, M | 1 |
| Sotgiu, G | 1 |
| D'Ambrosio, L | 1 |
| Raymundo, E | 1 |
| Fernandes, L | 1 |
| Barbedo, J | 1 |
| Diogo, N | 1 |
| Lange, C | 1 |
| Centis, R | 1 |
| Migliori, GB | 1 |
| Day, CP | 1 |
| Wang, JD | 1 |
| Chen, PC | 1 |
| BLASI, A | 1 |
| CURCI, G | 1 |
| CAMBA, R | 1 |
| KURTES, KM | 1 |
| HAND, G | 1 |
| WUNDER, M | 1 |
| FERENBACH, H | 1 |
| PREZIOSI, P | 1 |
| LA FIANZA, F | 1 |
| LAMANNA, G | 1 |
| FOURRIER, A | 1 |
| MICHAUX, P | 1 |
| CABANEL, G | 1 |
| CLERGET, O | 1 |
| THIODET, J | 1 |
| MILEWSKI, M | 1 |
| KRUCKEMEYER, K | 1 |
| KRUGER-THIEMER, E | 1 |
| GENOV, D | 1 |
| IWAINSKY, H | 1 |
| SIEGEL, D | 1 |
| BANCER, D | 1 |
| DE BENEDICTIS, G | 1 |
| CACUDI, G | 1 |
| GARBER, M | 1 |
| PETZEL, H | 1 |
| GRUNER, P | 1 |
| VETTER, HF | 1 |
| SCHNEIDER, HJ | 1 |
| STEPIEN, M | 1 |
| SZEWCZYKOWSKI, J | 1 |
| LEMERCIER, JP | 1 |
| DORDAIN, M | 1 |
| TISZAI, A | 1 |
| KOENYVES KOLONICS, L | 1 |
| MACSKASSY, O | 1 |
| RAJTAR-LEONTIEW, Z | 1 |
| ZALEWSKI, T | 1 |
| CHENEBAULT, J | 1 |
| HADNAGY, C | 1 |
| HUSZAR, I | 1 |
| TUSA, A | 1 |
| DUERR, F | 1 |
| MISSMAHL, HP | 1 |
| RISTICH, L | 1 |
| KOURTECHE, K | 1 |
| ROMINGER, E | 1 |
| LEZIAK, Z | 1 |
| PRZEMYSKA, B | 1 |
| Berkowitz, FE | 1 |
| Severens, JL | 1 |
| Blumberg, HM | 1 |
| Jinjuvadia, K | 1 |
| Kwan, W | 1 |
| Xia, YY | 1 |
| Zhan, SY | 1 |
| Marra, F | 1 |
| Marra, CA | 1 |
| Bruchet, N | 1 |
| Richardson, K | 1 |
| Moadebi, S | 1 |
| Elwood, RK | 1 |
| Fitzgerald, JM | 1 |
| Tayal, V | 1 |
| Kalra, BS | 1 |
| Agarwal, S | 1 |
| Khurana, N | 1 |
| Gupta, U | 1 |
| DeSwarte, RD | 1 |
| Bilynskiĭ, BT | 1 |
| Shparik, IaV | 1 |
| Gillette, JR | 1 |
| Salaspuro, M | 1 |
| van Berge Henegouwen, GP | 1 |
| Vogten, AJ | 1 |
| Holzbach, RT | 1 |
| Delanty, N | 1 |
| Vaughan, CJ | 1 |
| French, JA | 1 |
| West, RW | 1 |
| Kodell, RL | 1 |
| Pessayre, D | 1 |
| Benhamou, JP | 1 |
| Maddrey, WC | 1 |
| Boitnott, JK | 1 |
| Warrington, RJ | 1 |
| Tse, KS | 1 |
| Sherlock, S | 1 |
| Schwarz, JA | 1 |
| Laake, K | 1 |
| Borchgrevink, CF | 1 |
| Mitchell, JR | 2 |
| Lauterburg, BH | 2 |
| Nelson, SD | 1 |
| Thorgeirsson, SS | 1 |
| McMurtry, RJ | 1 |
| Dybing, E | 2 |
| Hashem, N | 1 |
| Shawki, R | 1 |
| Chapman, CJ | 1 |
| Cohmen, G | 1 |
| Zimmerman, HJ | 1 |
| Dal-Ré, R | 1 |
| Hennigar, GR | 1 |
| Dorfmann, H | 1 |
| Kahn, MF | 1 |
| de Sèze, S | 1 |
| Vesell, ES | 1 |
| Harpey, JP | 1 |
| Waller, HD | 1 |
| Wurm, K | 1 |
| Bischoff, A | 1 |
| Cohen, SN | 1 |
| Weber, WW | 1 |
| Fishbein, L | 1 |
| Flamm, WG | 1 |
| Wepler, R | 1 |
| Rommel, K | 1 |
| Goedde, W | 1 |
| Weinstein, L | 1 |
| Dalton, AC | 1 |
| Schmid, M | 1 |
| Waser, PG | 1 |
| Scheid, W | 1 |
| Orlowski, EH | 1 |
| Kalow, W | 1 |
| Brückner, R | 1 |
| Quinn, B | 1 |
| Gagné, F | 1 |
| Blaise, C | 1 |
| Pascoe, D | 1 |
| Karntanut, W | 1 |
| Müller, CT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Trial to Compare Effectiveness of 4 Months Rifampin (4 RIF) With 9 Months Isoniazid (9 INH) in the Prevention of Active TB in Children: The P4v9 Trial[NCT00170209] | Phase 3 | 844 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| A Randomized Clinical Trial of 4 Months of Rifampin vs. 9 Months of Isoniazid for Latent Tuberculosis Infection. Part 3 - Effectiveness[NCT00931736] | Phase 3 | 6,031 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| A Randomised, Pragmatic, Open-Label Trial To Evaluate The Effect Of Three Months Of High Dose Rifapentine Plus Isoniazid Administered As A Single Round Or Given Annually In HIV-Positive Individuals[NCT02980016] | Phase 3 | 4,027 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection[NCT00023452] | Phase 3 | 8,053 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| Efficacy of Risk-Targeted Video Based Directly on Observed Therapy for Latent TB[NCT03783728] | 0 participants (Actual) | Observational | 2019-06-30 | Withdrawn (stopped due to Investigator is leaving the University) | |||
| TBTC Study 33. An Evaluation of Adherence to Latent Tuberculosis Infection (LTBI) Treatment With 12 Doses of Once Weekly Rifapentine (RPT) and Isoniazid (INH) Given as Self-administered (SAT) Versus Directly-observed Therapy (DOT): iAdhere.[NCT01582711] | Phase 3 | 1,002 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Cumulative TB disease rate was defined as number of participants (regardless of age) with culture-confirmed TB disease (defined as positive culture for MTB]) or probable (clinical) TB disease (defined as objective evidence of clinical TB disease [cough, fever, night sweats, weight loss, or hemoptysis] based on history or physical exam plus radiograph, CT scan, other diagnostic tests PLUS response to antituberculosis therapy AND objective improvement of radiograph or other diagnostic tests; OR evidence of granuloma with organism positive for AFB, or caseating granulomata at autopsy or biopsy) between enrollment and the 990th Day of the Trial (33 months after enrollment, or end of the trial) per 100 participants w/33 months of follow-up and was calculated using survival analysis methods (Kaplan-Meier approach). (NCT00023452)
Timeframe: Baseline up to 33 Months
| Intervention | TB cases per 100 participants w/followup (Number) |
|---|---|
| 9INH | 0.49 |
| 3RPT/INH | 0.24 |
Cumulative TB disease rate was defined as number of participants ≥18 years old with culture-confirmed TB disease (defined as positive culture for MTB) and <18 years old with probable (clinical) TB disease (defined as objective evidence of clinical TB disease [cough, fever, night sweats, weight loss, or hemoptysis] based on history or physical exam plus radiograph, CT scan, other diagnostic tests PLUS response to antituberculosis therapy AND objective improvement of radiograph or other diagnostic tests; OR evidence of granuloma with organism positive for AFB], or caseating granulomata at autopsy or biopsy) between enrollment and 33 months after enrollment (for those who completed therapy within 33 months) per 100 participants w/33 months of follow-up and was calculated using survival analysis methods (Kaplan-Meier approach). (NCT00023452)
Timeframe: Baseline up to Month 33
| Intervention | TB cases per 100 participants w/followup (Number) |
|---|---|
| 9INH | 0.11 |
| 3RPT/INH | 0.05 |
Cumulative TB disease rate was defined as number of participants ≥18 years old with culture-confirmed TB disease (defined as positive culture for MTB) and those <18 years old with probable (clinical) TB disease (defined as objective evidence of clinical TB disease [cough, fever, night sweats, weight loss, or hemoptysis] based on history or physical exam plus radiograph, CT scan, other diagnostic tests PLUS response to antituberculosis therapy AND objective improvement of radiograph or other diagnostic tests; OR evidence of granuloma with organism positive for AFB], or caseating granulomata at autopsy or biopsy) between enrollment and 24 months after completion of study therapy per 100 participants with up to 33 months of follow-up and was calculated using survival analysis methods (Kaplan-Meier approach). (NCT00023452)
Timeframe: Baseline up to Month 27 (3RPT/INH) or Month 33 (9INH)
| Intervention | TB cases per 100 participants w/followup (Number) |
|---|---|
| 9INH | 0.37 |
| 3RPT/INH | 0.16 |
Cumulative TB disease rate defined as number of participants ≥18 years old with culture-confirmed TB disease (defined as positive culture for Mycobacterium tuberculosis [MTB]) and those <18 years old with probable (clinical) TB disease (defined as objective evidence of clinical TB disease [cough, fever, night sweats, weight loss, or hemoptysis] based on history or physical exam plus radiograph, computed tomography [CT] scan, other diagnostic tests PLUS response to antituberculosis therapy AND objective improvement of radiograph or other diagnostic tests; OR evidence of granuloma with organism positive for acid-fast bacilli [AFB], or caseating granulomata at autopsy or biopsy) between enrollment and the 990th Day of the Trial (33 months after enrollment, or end of the trial) per 100 participants with (w/)33 months of follow-up calculated using survival analysis methods (Kaplan-Meier approach). (NCT00023452)
Timeframe: Baseline up to Month 33
| Intervention | TB cases per 100 participants w/followup (Number) |
|---|---|
| 9INH | 0.43 |
| 3RPT/INH | 0.19 |
Completion in the 3RPT/INH arm was defined as: received 12 doses of RPT/INH within 16 weeks (12 weeks optimal). However, participants were considered to have completed therapy if at least 11 doses of RPT/INH had been received (~90%) during the 16-week time period. Completion in the 9INH arm was defined as: received 270 doses of INH within 52 weeks (39 weeks optimal). However, participants were considered to have completed therapy if at least 240 doses of INH were received (~90%) during the 52-week period. (NCT00023452)
Timeframe: Baseline up to Month 3 (3RPT/INH) or Month 9 (9INH)
| Intervention | percentage of participants (Number) |
|---|---|
| 9INH | 69.0 |
| 3RPT/INH | 82.1 |
(NCT00023452)
Timeframe: Baseline up to Month 35
| Intervention | percentage of participants (Number) |
|---|---|
| 9INH | 1.0 |
| 3RPT/INH | 0.8 |
Discontinuation of study drug due to an adverse drug reaction associated with either 3RPT/INH or 9INH was defined as discontinuing treatment and/or study due to a treatment-related adverse event (AE) (considered either possibly, probably, or definitely related to the study drug by the investigator). (NCT00023452)
Timeframe: Baseline up to 60 days after the last dose of study drug (Month 5 [3RPT/INH] or Month 11 [9INH])
| Intervention | percentage of participants (Number) |
|---|---|
| 9INH | 3.8 |
| 3RPT/INH | 4.9 |
Drug discontinuations for any reason associated with 3RPT/INH or 9INH included all reasons for discontinuation from study treatment, regardless of relationship to treatment. (NCT00023452)
Timeframe: Baseline up to Month 3 (3RPT/INH) or Month 9 (9INH)
| Intervention | percentage of participants (Number) |
|---|---|
| 9INH | 31.0 |
| 3RPT/INH | 17.9 |
Drug-susceptibility testing (DST) was performed on isolates of MTB obtained from participants who developed signs and symptoms of active TB disease (including sputum specimens or specimens from appropriate body site for extrapulmonary TB disease). DST was performed at site's local laboratory and sent to Sponsor for confirmatory susceptibility testing. DST included all drugs currently used to treat TB disease, including pyrazinamide (PZA) and fluoroquinolones. Susceptibility was tested for other drugs at the Sponsor laboratory at the following concentrations: INH, 0.02, 1.0, and 5.0 micrograms per milliliter (µg/mL) and rifampin (RIF), 1.0 µg/mL. Isolates resistant to RIF were assumed to be resistant to RPT. (NCT00023452)
Timeframe: Baseline up to Month 33
| Intervention | percentage of participants (Number) | |
|---|---|---|
| INH monoresistance | RIF and PZA resistant | |
| 3RPT/INH | 0 | 14 |
| 9INH | 15 | 0 |
Drug toxicities (or AEs) were graded using Common Toxicity Criteria (CTC version 2.0, Publish Date April 30, 1999, Cancer Therapy Evaluation Program). Grade 3 and 4 drug toxicities associated with 3RPT/INH or 9INH were defined as treatment-related Grade 3 or 4 AEs (considered either possibly, probably, or definitely related to the study drug by the investigator). (NCT00023452)
Timeframe: Baseline up to 60 days after the last dose of study drug (Month 5 [3RPT/INH] or Month 11 [9INH])
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Grade 3 | Grade 4 | |
| 3RPT/INH | 2.7 | 0.4 |
| 9INH | 2.2 | 0.4 |
25 reviews available for isoniazid and Adverse Drug Event
| Article | Year |
|---|---|
Genetics of drug-induced liver injury: Current knowledge and future prospects.
Topics: Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Adverse Reactions; Genotype; H | 2023 |
Metabolomics describes previously unknown toxicity mechanisms of isoniazid and rifampicin.
Topics: Animals; Antitubercular Agents; Biomarkers; Biotransformation; Drug-Related Side Effects and Adverse | 2020 |
Drug-induced lupus: an update on its dermatologic aspects.
Topics: Anti-Arrhythmia Agents; Anti-Bacterial Agents; Antihypertensive Agents; Antitubercular Agents; Autoa | 2009 |
Drug-induced liver injury: past, present and future.
Topics: Alleles; Amoxicillin-Potassium Clavulanate Combination; Arylamine N-Acetyltransferase; Chemical and | 2010 |
Predicting and preventing acute drug-induced liver injury: what's new in 2010?
Topics: Acetaminophen; Adult; Aged; Aging; Alanine Transaminase; Amoxicillin-Potassium Clavulanate Combinati | 2010 |
Liver injury caused by drugs: an update.
Topics: Acetaminophen; Adaptive Immunity; Analgesics, Non-Narcotic; Antitubercular Agents; Apoptosis; Chemic | 2010 |
Genetic association studies in drug-induced liver injury.
Topics: Antitubercular Agents; Case-Control Studies; Chemical and Drug Induced Liver Injury; Drug-Related Si | 2012 |
[Systematic review of anti-tuberculosis drug induced adverse reactions in China].
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; China; Drug-Related Side Effects and | 2007 |
[Carcinogenicity of various drugs].
Topics: Adult; Animals; Anti-Bacterial Agents; Arsenicals; Barbiturates; Brain Neoplasms; Carcinogens; Child | 1984 |
The problem of chemically reactive metabolites.
Topics: Acetaminophen; Animals; Biotransformation; Chemical Phenomena; Chemistry; Chloroform; Drug-Related S | 1982 |
Drug-induced liver injury.
Topics: Age Factors; Bile; Biotransformation; Chemical and Drug Induced Liver Injury; Dose-Response Relation | 1980 |
Drug-induced liver disease.
Topics: Analgesics; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Chlorpromazine; Contracep | 1981 |
Medical causes of seizures.
Topics: Acute Kidney Injury; Anticonvulsants; Antitubercular Agents; Blood Pressure; Brain Diseases; Broncho | 1998 |
Drug-induced chronic hepatitis and cirrhosis.
Topics: Adult; Aged; Chemical and Drug Induced Liver Injury; Cholestasis; Drug-Related Side Effects and Adve | 1979 |
Metabolic activation: biochemical basis for many drug-induced liver injuries.
Topics: Acetaminophen; Animals; Binding Sites; Carcinogens; Chemical and Drug Induced Liver Injury; Drug Hyp | 1976 |
[Drug damage to the liver: role of reactive metabolites and pharmacokinetics].
Topics: Acetaminophen; Amiodarone; Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Adv | 1985 |
[Iatrogenic lupus: present status of the problem. II. Physiopathology of induced lupus].
Topics: Animals; Antibodies, Antinuclear; Disease Models, Animal; DNA, Viral; Drug-Related Side Effects and | 1972 |
Advances in pharmacogenetics.
Topics: Alcohol Oxidoreductases; Catalase; Cholinesterases; Dicumarol; Diseases in Twins; Drug Hypersensitiv | 1973 |
Lupus-like syndromes induced by drugs.
Topics: Antibodies, Antinuclear; Antibody Formation; Arthritis, Rheumatoid; Chlorpromazine; DNA, Single-Stra | 1974 |
[Adverse effects of drugs in hereditary variants in the enzyme apparatus of the body].
Topics: Adenosine Triphosphatases; Adult; Aged; Cholinesterase Inhibitors; Coumarins; Dibucaine; Drug-Relate | 1968 |
[Therapy of sarcoidosis].
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Adult; Antineoplastic Agents; Chloroquine; Dru | 1966 |
Pharmacogenetics.
Topics: Analgesics; Anemia, Hemolytic; Anesthetics; Apnea; Bone Marrow Diseases; Child; Child, Preschool; Ch | 1972 |
Potential environmental chemical hazards. I. Drugs.
Topics: Abnormalities, Drug-Induced; Alkylating Agents; Analgesics; Animals; Aspirin; Carcinogens; Drug-Rela | 1972 |
[Drugs and parameters in the laboratory medicine].
Topics: Aminosalicylic Acids; Aspirin; Blood Cell Count; Chlorpromazine; Chlorpropamide; Circadian Rhythm; C | 1973 |
Host determinants of response to antimicrobial agents.
Topics: Anemia, Hypochromic; Anemia, Pernicious; Anti-Infective Agents; Cystic Fibrosis; Diabetes Complicati | 1968 |
3 trials available for isoniazid and Adverse Drug Event
| Article | Year |
|---|---|
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Topics: Adolescent; Adult; Antitubercular Agents; Drug-Related Side Effects and Adverse Reactions; Female; H | 2015 |
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Topics: Adolescent; Adult; Antitubercular Agents; Drug-Related Side Effects and Adverse Reactions; Female; H | 2015 |
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Topics: Adolescent; Adult; Antitubercular Agents; Drug-Related Side Effects and Adverse Reactions; Female; H | 2015 |
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Topics: Adolescent; Adult; Antitubercular Agents; Drug-Related Side Effects and Adverse Reactions; Female; H | 2015 |
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Topics: Adolescent; Adult; Antitubercular Agents; Drug-Related Side Effects and Adverse Reactions; Female; H | 2015 |
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Topics: Adolescent; Adult; Antitubercular Agents; Drug-Related Side Effects and Adverse Reactions; Female; H | 2015 |
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Topics: Adolescent; Adult; Antitubercular Agents; Drug-Related Side Effects and Adverse Reactions; Female; H | 2015 |
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Topics: Adolescent; Adult; Antitubercular Agents; Drug-Related Side Effects and Adverse Reactions; Female; H | 2015 |
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Topics: Adolescent; Adult; Antitubercular Agents; Drug-Related Side Effects and Adverse Reactions; Female; H | 2015 |
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Topics: Adolescent; Adult; Antitubercular Agents; Drug-Related Side Effects and Adverse Reactions; Female; H | 2015 |
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Topics: Adolescent; Adult; Antitubercular Agents; Drug-Related Side Effects and Adverse Reactions; Female; H | 2015 |
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Topics: Adolescent; Adult; Antitubercular Agents; Drug-Related Side Effects and Adverse Reactions; Female; H | 2015 |
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Topics: Adolescent; Adult; Antitubercular Agents; Drug-Related Side Effects and Adverse Reactions; Female; H | 2015 |
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Topics: Adolescent; Adult; Antitubercular Agents; Drug-Related Side Effects and Adverse Reactions; Female; H | 2015 |
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Topics: Adolescent; Adult; Antitubercular Agents; Drug-Related Side Effects and Adverse Reactions; Female; H | 2015 |
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Topics: Adolescent; Adult; Antitubercular Agents; Drug-Related Side Effects and Adverse Reactions; Female; H | 2015 |
Lack of cross-toxicity between isoniazid and ethionamide in severe cutaneous adverse drug reactions: a series of 25 consecutive confirmed cases.
Topics: Adolescent; Adult; Antitubercular Agents; Drug Interactions; Drug-Related Side Effects and Adverse R | 2015 |
Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons.
Topics: Adolescent; Adult; Americas; Antitubercular Agents; Asia; Child; Drug-Related Side Effects and Adver | 2016 |
Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons.
Topics: Adolescent; Adult; Americas; Antitubercular Agents; Asia; Child; Drug-Related Side Effects and Adver | 2016 |
Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons.
Topics: Adolescent; Adult; Americas; Antitubercular Agents; Asia; Child; Drug-Related Side Effects and Adver | 2016 |
Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons.
Topics: Adolescent; Adult; Americas; Antitubercular Agents; Asia; Child; Drug-Related Side Effects and Adver | 2016 |
93 other studies available for isoniazid and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Dru | 2004 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Bi | 2008 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2012 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
High Burden of Adverse Drug Reactions to Isoniazid Preventive Therapy in People Living With HIV at 3 Tertiary Hospitals in Uganda: Associated Factors.
Topics: Antitubercular Agents; Child; Cross-Sectional Studies; Drug-Related Side Effects and Adverse Reactio | 2022 |
Whole-Blood 3-Gene Signature as a Decision Aid for Rifapentine-based Tuberculosis Preventive Therapy.
Topics: Antitubercular Agents; Decision Support Techniques; Drug Therapy, Combination; Drug-Related Side Eff | 2022 |
Analysis of Adverse Drug Reactions to First-Line Anti-Tuberculosis Drugs Using the Korea Adverse Event Reporting System.
Topics: Antitubercular Agents; Drug-Related Side Effects and Adverse Reactions; Ethambutol; Humans; Isoniazi | 2022 |
Isoniazid level and flu-like symptoms during rifapentine-based tuberculosis preventive therapy: A population pharmacokinetic analysis.
Topics: Antitubercular Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; H | 2023 |
Management of tuberculosis infection in Victorian children: A retrospective clinical audit of factors affecting treatment completion.
Topics: Adolescent; Antitubercular Agents; Child; Clinical Audit; Drug-Related Side Effects and Adverse Reac | 2022 |
Symptoms and Systemic Drug Reactions in Persons Receiving Weekly Rifapentine Plus Isoniazid (3HP) Treatment for Latent Tuberculosis Infection.
Topics: Antitubercular Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; F | 2023 |
Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials.
Topics: Adult; Africa; Americas; Antitubercular Agents; Asia; Australia; Clinical Trials, Phase II as Topic; | 2020 |
Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials.
Topics: Adult; Africa; Americas; Antitubercular Agents; Asia; Australia; Clinical Trials, Phase II as Topic; | 2020 |
Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials.
Topics: Adult; Africa; Americas; Antitubercular Agents; Asia; Australia; Clinical Trials, Phase II as Topic; | 2020 |
Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials.
Topics: Adult; Africa; Americas; Antitubercular Agents; Asia; Australia; Clinical Trials, Phase II as Topic; | 2020 |
Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis.
Topics: Adult; Antitubercular Agents; Arylamine N-Acetyltransferase; Cytochrome P-450 Enzyme System; Drug Ad | 2019 |
Cocrystallization with syringic acid presents a new opportunity for effectively reducing the hepatotoxicity of isoniazid.
Topics: Animals; Chemical and Drug Induced Liver Injury; Crystallization; Drug-Related Side Effects and Adve | 2020 |
Use of Rifampin Compared with Isoniazid for the Treatment of Latent Tuberculosis Infection in Japan: A Bayesian Inference with Markov Chain Monte Carlo Method.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Bayes Theorem; Drug Administration Schedule; | 2020 |
Evidence of drug-induced hepatotoxicity in the Maghrebian population.
Topics: Adolescent; Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug-Related Side | 2022 |
The Outcome of Accidental Bacille Calmette-Guérin Overdose During Routine Neonatal Immunization.
Topics: Accidents; Anti-Bacterial Agents; BCG Vaccine; Drug-Related Side Effects and Adverse Reactions; Huma | 2021 |
High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection.
Topics: Adolescent; Adult; Aged; Antibiotics, Antitubercular; Antitubercular Agents; Child; Child, Preschool | 2017 |
Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: High rates of adverse events.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, C | 2019 |
Revised Antituberculosis Drug Doses and Hepatotoxicity in HIV Negative Children.
Topics: Adolescent; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; | 2019 |
Intestinal dysbiosis compromises alveolar macrophage immunity to Mycobacterium tuberculosis.
Topics: Animals; Antibiotics, Antitubercular; Disease Models, Animal; Drug-Related Side Effects and Adverse | 2019 |
Intermediate to long-term follow-up results of INH chemoprophylaxis prior to anti-TNF-alpha therapy in a high-risk area for tuberculosis.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Antitubercular Agents; Chemoprevention; Drug-Related | 2013 |
[Evaluation of multidrug-resistant tuberculosis treatment in Ivory Coast from 2008 to 2010].
Topics: Adult; Antitubercular Agents; Cote d'Ivoire; Drug-Related Side Effects and Adverse Reactions; Ethamb | 2013 |
Under-reporting and Poor Adherence to Monitoring Guidelines for Severe Cases of Isoniazid Hepatotoxicity.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Antitubercular Agents; Chemical an | 2015 |
Isoniazid poisoning: Pharmacokinetics and effect of hemodialysis in a massive ingestion.
Topics: Adult; Drug Overdose; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Isoniazid; Re | 2015 |
High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Cameroon; Clofazimine; Cohort Studies; Confidence In | 2015 |
Reducing Risk of Severe Liver Injury in Patients Treated With Isoniazid.
Topics: Adverse Drug Reaction Reporting Systems; Antitubercular Agents; Chemical and Drug Induced Liver Inju | 2015 |
N-acetyltransferase 2 (NAT2) gene polymorphism as a predisposing factor for phenytoin intoxication in tuberculous meningitis or tuberculoma patients having seizures - A pilot study.
Topics: Acetylation; Adult; Arylamine N-Acetyltransferase; Drug Combinations; Drug-Related Side Effects and | 2016 |
Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar.
Topics: Adult; Antitubercular Agents; Diabetes Complications; Dose-Response Relationship, Drug; Drug Therapy | 2017 |
Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis.
Topics: Acetamides; Adult; Amikacin; Antitubercular Agents; Capreomycin; Drug-Related Side Effects and Adver | 2011 |
Case-crossover design: an alternative strategy for detecting drug-induced liver injury.
Topics: Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Chemica | 2012 |
[Acute and chronic isonicotinic acid hydrazide poisoning; experimental research on the guinea pig].
Topics: Drug-Related Side Effects and Adverse Reactions; Guinea Pigs; Isomerism; Isoniazid; Niacin; Nicotini | 1952 |
[On a case of fatal isoniazid poisoning].
Topics: Drug-Related Side Effects and Adverse Reactions; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Pois | 1953 |
[A case of intentional isoniazid poisoning].
Topics: Drug-Related Side Effects and Adverse Reactions; Isoniazid; Niacin; Nicotinic Acids; Poisoning; Suic | 1954 |
[Crush syndrome caused by isoniazid poisoning].
Topics: Crush Syndrome; Drug-Related Side Effects and Adverse Reactions; Isomerism; Isoniazid; Niacin; Nicot | 1954 |
[Arginine action on ammonium salt and isoniazid poisoning].
Topics: Ammonium Compounds; Arginine; Drug-Related Side Effects and Adverse Reactions; Isoniazid; Quaternary | 1956 |
[Suicide attempt with rimifon].
Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Isoniazid; Suicide; Suicide, Attempted | 1957 |
[Acute poisoning in 3-year-old child caused by isonicotinic acid hydrazide].
Topics: Child; Drug-Related Side Effects and Adverse Reactions; Humans; Isoniazid | 1957 |
[Acute fatal poisoning with isonicotinic acid hydrazide (Neoteben-Bayer)].
Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Isoniazid | 1957 |
[Acute isoniazid poisoning].
Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Isoniazid; Suicide | 1958 |
[A case of acute poisoning with rimifon (isonicotinic acid hydrazide) with the purpose of committing suicide].
Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Isoniazid; Suicide | 1957 |
[Decrease of isonicotinic acid hydrazide toxicity by pyruvic acid].
Topics: Drug-Related Side Effects and Adverse Reactions; Isoniazid; Pyruvates; Pyruvic Acid | 1958 |
[A case of poisoning caused by a lethal dose of isonicotinic acid hydrazid].
Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Isoniazid; Isonicotinic Acids; Suicide | 1959 |
[Experimental research on the possible protective action of thioctic acid in acute isonicotinic acid hydrazide poisoning. II].
Topics: Drug-Related Side Effects and Adverse Reactions; Isoniazid; Thioctic Acid; Vitamin A; Vitamin K; Vit | 1959 |
[Acute poisoning by isonicotinic acid hydrazide in attempted suicide; case report].
Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Isoniazid; Suicide; Suicide, Attempted | 1959 |
[Suicidal isonicotinic acid hydrazide poisoning and its treatment].
Topics: Drug-Related Side Effects and Adverse Reactions; Isoniazid; Suicidal Ideation; Suicide | 1960 |
[Fatal isonicotinic acid hydrazide poisoning. (Suicide with 10g INH)].
Topics: Drug-Related Side Effects and Adverse Reactions; Isoniazid; Suicide | 1959 |
[On acute isonicotinic acid hydrazide poisoning and its treatment].
Topics: Drug-Related Side Effects and Adverse Reactions; Isoniazid | 1961 |
[On the problem of the symptomatology in acute isonicotinic acid hydrazide poisoning. Report of 3 cases].
Topics: Drug-Related Side Effects and Adverse Reactions; Isoniazid; Neurologic Manifestations | 1961 |
[ACUTE INTOXICATION BY ISONIAZID].
Topics: Acidosis; Bicarbonates; Blood Gas Analysis; Coma; Drug-Related Side Effects and Adverse Reactions; H | 1963 |
[CONTRIBUTION TO THE CLINICAL ASPECTS OF ACUTE ISONIAZID INTOXICATION].
Topics: Drug-Related Side Effects and Adverse Reactions; Isoniazid; Psychoses, Substance-Induced; Suicide; T | 1963 |
[ACCIDENTAL INH POISONING IN A 2-YEAR-OLD GIRL].
Topics: Drug-Related Side Effects and Adverse Reactions; Infant; Isoniazid; Phenobarbital; Seizures; Toxicol | 1964 |
[ACUTE ISONIAZID POISONING].
Topics: Clinical Laboratory Techniques; Diagnosis; Drug-Related Side Effects and Adverse Reactions; Isoniazi | 1964 |
[APROPOS OF A CASE OF ACUTE ISONIAZID POISONING].
Topics: Drug-Related Side Effects and Adverse Reactions; Isoniazid; Suicide; Toxicology | 1964 |
[EXTRACORPOREAL HEMODIALYSIS IN ACUTE ISONIAZID POISONING. CONTRIBUTION TO THE STUDIES ON THE DIALYSABILITY OF ISONIAZID].
Topics: Drug-Related Side Effects and Adverse Reactions; Isoniazid; Kidney; Kidneys, Artificial; Renal Dialy | 1965 |
[A case of acute isoniazid poisoning].
Topics: Drug-Related Side Effects and Adverse Reactions; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Pois | 1954 |
[INH poisoning in childhood].
Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Isoniazid | 1960 |
[Acute suicidal isonicotinic acid hydrazide poisoning].
Topics: Drug-Related Side Effects and Adverse Reactions; Isoniazid; Suicidal Ideation; Suicide | 1962 |
Exposure to tuberculosis among newborns in a nursery: decision analysis for initiation of prophylaxis.
Topics: Acquired Immunodeficiency Syndrome; Antibiotic Prophylaxis; Antitubercular Agents; Decision Support | 2006 |
Searching for a needle in a haystack: use of ICD-9-CM codes in drug-induced liver injury.
Topics: Adolescent; Adult; Aged; Amoxicillin-Potassium Clavulanate Combination; Chemical and Drug Induced Li | 2007 |
Adverse drug reactions associated with first-line anti-tuberculosis drug regimens.
Topics: Antitubercular Agents; Drug-Related Side Effects and Adverse Reactions; Humans; Isoniazid; Pyrazinam | 2007 |
Hepatoprotective effect of tocopherol against isoniazid and rifampicin induced hepatotoxicity in albino rabbits.
Topics: Animals; Antioxidants; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Cimetidine; Do | 2007 |
Drug allergy--problems and strategies.
Topics: Anaphylaxis; Anemia, Hemolytic; Antigen-Antibody Complex; Desensitization, Immunologic; Dose-Respons | 1984 |
[Drug-induced liver damage; new aspects on its mechanism].
Topics: Acetaminophen; Chemical and Drug Induced Liver Injury; Chlorpromazine; Contraceptives, Oral; Drug-Re | 1980 |
A comparison of methods of benchmark-dose estimation for continuous response data.
Topics: Animals; Antitubercular Agents; Benchmarking; Bias; Computer Simulation; Confidence Intervals; Dose- | 1999 |
[Reactive metabolites of xenobiotics : their role in the hepatotoxicity of drugs].
Topics: Acetaminophen; Animals; Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme System; Drug | 1979 |
Lymphocyte transformation studies in drug hypersensitivity.
Topics: Chemical and Drug Induced Liver Injury; Drug Hypersensitivity; Drug-Related Side Effects and Adverse | 1979 |
Hepatic reactions to drugs.
Topics: Acetaminophen; Adenoma; Adult; Carbon Tetrachloride Poisoning; Chemical and Drug Induced Liver Injur | 1979 |
[Drug-induced disorders of lupus erythematosus type (author's transl)].
Topics: Animals; Antibody Formation; Anticonvulsants; Chlorpromazine; Drug-Related Side Effects and Adverse | 1977 |
[Drug-induced liver disease].
Topics: Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Adverse Reactions; Humans; Iso | 1978 |
Drug-induced liver injury.
Topics: Acetaminophen; Animals; Chemical and Drug Induced Liver Injury; Drug Hypersensitivity; Drug-Related | 1978 |
Cultured peripheral lymphocytes: one biologic indicator of potential drug hazard.
Topics: Adolescent; Antimony; Antimony Potassium Tartrate; Child; Child, Preschool; Chromosomes, Human; Drug | 1976 |
Drugs and genes: therapeutic implications.
Topics: Acetylation; Administration, Topical; Anemia, Hemolytic; Anti-Inflammatory Agents; Drug-Related Side | 1977 |
[Drug-induced lupus erythematosus-like syndromes].
Topics: Adolescent; Adult; Aged; Antibodies, Antinuclear; Anticonvulsants; Drug-Related Side Effects and Adv | 1976 |
Liver disease caused by medicinal agents.
Topics: Adrenal Cortex Hormones; Analgesics; Chemical and Drug Induced Liver Injury; Cholestasis; Contracept | 1975 |
[Drug induced liver injury. Chemical liver necrosis caused by formation of reactive metabolites].
Topics: Acetaminophen; Animals; Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme System; Drug | 1976 |
[Clinical trial of drugs: a study of the influence of information on adverse reactions on obtaining of informed consent].
Topics: Adult; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Female; Humans; In | 1991 |
Iatrogenic drug toxicity.
Topics: Acetaminophen; Age Factors; Amphotericin B; Chemical and Drug Induced Liver Injury; Drug Interaction | 1985 |
Drugs and genes.
Topics: Acetyltransferases; Drug Antagonism; Drug Hypersensitivity; Drug Interactions; Drug-Related Side Eff | 1973 |
Psychiatric side effects of nonpsychiatric drugs.
Topics: Aminophylline; Analgesics; Anti-Anxiety Agents; Anti-Bacterial Agents; Anticonvulsants; Antiemetics; | 1971 |
[Drug-induced polyneuropathy].
Topics: Abnormalities, Drug-Induced; Adult; Animals; Drug-Related Side Effects and Adverse Reactions; Female | 1970 |
[Pharmacologic basis of metabolic disturbances and drug incompatibilities].
Topics: Cholinesterases; Drug-Related Side Effects and Adverse Reactions; Isoniazid; Pharmacogenetics; Pheny | 1973 |
[Hepatotoxic reactions caused by drugs].
Topics: Adolescent; Aminosalicylic Acids; Anabolic Agents; Bilirubin; Carbon Tetrachloride Poisoning; Chemic | 1967 |
[Pharmacogenetics].
Topics: Anemia, Hemolytic; Antipyrine; DNA; Drug-Related Side Effects and Adverse Reactions; Europe; Glucose | 1967 |
The clinical importance of pharmacogenetics.
Topics: Adult; Aged; Child, Preschool; Chromosome Aberrations; Chromosome Disorders; Congenital Abnormalitie | 1969 |
[Toxic polyneuritis].
Topics: Arsenic; Drug-Related Side Effects and Adverse Reactions; Ethanol; Germany, West; Humans; Isoniazid; | 1970 |
[Standard therapy of tuberculosis].
Topics: Antitubercular Agents; Body Weight; Drug-Related Side Effects and Adverse Reactions; Ethambutol; Hum | 1971 |
Genetic factors in adverse drug reactions.
Topics: Anesthesia, General; Barbiturates; Cholinesterases; Drug-Related Side Effects and Adverse Reactions; | 1971 |
[Early diagnosis of drug damage to the retina and optic nerve].
Topics: Adult; Aged; Anti-Bacterial Agents; Anticoagulants; Antimalarials; Chlorpromazine; Contraceptives, O | 1969 |
The effects of pharmaceuticals on the regeneration of the cnidarian, Hydra attenuata.
Topics: Algorithms; Analgesics, Non-Narcotic; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non- | 2008 |
Do pharmaceuticals affect freshwater invertebrates? A study with the cnidarian Hydra vulgaris.
Topics: Animals; Drug-Related Side Effects and Adverse Reactions; Hydra; Lethal Dose 50; Risk Assessment; Su | 2003 |